Muscarinic signaling in the central nervous system: Recent developments and anesthetic implications

Anesthesiology

Volumn 84, Issue 1, 1996, Pages 173-189

  Durieux, Marcel E ^a,b  

^a Dept of Anesth and Neurosurgery ^*  (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Analgesia: spinal mechanisms; Anesthetic mechanisms; Parasympathetic nervous system; Receptors: muscarinic acetylcholine: nicotinic

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 3 (6 CHLORO 2 PYRAZINYL)QUINUCLIDINE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINE; ATROPINE; CARBACHOL; CHOLINESTERASE INHIBITOR; DROPERIDOL; GLYCOPYRRONIUM BROMIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOTHANE; HEXAHYDROSILADIFENIDOL; HIMBACINE; METHACHOLINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEOSTIGMINE; OTENZEPAD; PHYSOSTIGMINE; PIRENZEPINE; SCOPOLAMINE;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; BRAIN PROTECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG RECEPTOR BINDING; GENERAL ANESTHESIA; HUMAN; HUMAN EXPERIMENT; INTRATHECAL DRUG ADMINISTRATION; MOLECULAR CLONING; MOTION SICKNESS; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RAT; REVIEW; SEDATION; TRANSDERMAL DRUG ADMINISTRATION; VOMITING; XENOPUS;

ANESTHETICS; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 0030046875     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199601000-00020     Document Type: Review

References (171)

1. Dale HH: The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 1914; 6:147-96
2. Loewi O, Navratil E: Über humorale Übertrachbarkeit der Herznervenwirkung. XI. Über den Mechanismus der Vaguswirkung von Physstigmin und Ergotamin. Pflügers Arch 1926; 214:689-96
3. Stedman E, Stedman E, Easson LH: Cholinesterase. An enzyme present in blood-sera from horse. Biochem J 1932; 26:2056-66
4. Hammill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981; 391: 85-100
5. Neher E, Sakmann B: Single channel currents recorded from membrane of denervated frog muscle fibers. Nature 1976; 260:799-802
6. Raftery MA, Dunn SM, Conti-Tronconi BM, Middlemas DS, Crawford RD: The nicotinic acetylcholine receptor: subunit structure, functional binding sites, and ion transport properties. Cold Spring Harb Symp Quant Biol 1983; Pt 1:21-33
7. Noda M, Takahashi H, Tanabe T, Toyosato M, Furutani Y, Hirose T, Asai M, Inayama S, Miyata T, Numa S: Primary structure of α-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature 1982; 299:793-7
8. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, Haga T, Haga K, Ichiyama A, Kangawa K, Kojima M, Matsuo H, Hirose T, Numa S: Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor Nature 1986; 323:411-6
9. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC: Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980; 283:90-2
10. 3H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: Evidence for the existence of three classes of binding sites. Mol Pharmacol 1986; 30:305-14
11. Waelbroeck M, Gillard M, Robberecht P, Christophe J: Muscarinic receptor heterogeneity in rat central nervous system. I. Binding of four selective antagonists to three muscarinic receptor subclasses: A comparison with M2 cardiac muscarinic receptors of the C type. Mol Pharmacol 1987; 32:91-9
12. 4) in rat forebrain. Mol Pharmacol 1990; 38:267-73
13. Caulfield MP: Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993; 58:319-79
14. Yost CS: G proteins: Basic characteristics and clinical potential for the practice of anesthesia Anesth Analg 1993; 77:822-34
15. Lynch C, Jaeger JM: The G protein cell signalling system, Advances in Anesthesia 11. Edited by Lake CL. Chicago, Mosby-Year Book, Inc. 1994, pp 65-112
16. Kubo T, Makada A, Sugimoto K, Akiba I, Mikani A, Takahashi H, Haga T, Haga K, Ichiyama A, Kangawa K, Numa S: Primary structure of porcine cardiac muscarinic receptor deduced from the cDNA sequence. FEBS Lett 1987; 209:367-72
17. Peralta EG: Primary structure and biochemical properties of an M2 muscarinic receptor. Science 1987; 236:600-5
18. Bonner TI, Buckley NJ, Young AC, Brann MR: Identification of a family of muscarinic acctylcholine receptors. Science 1987; 237:527-32
19. Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988; 1:403-10
20. Peralta EG: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors Embo J 1987; 6:3923-9
21. Bonner TI: The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12:148-51
22. Trimmer BA: Current excitement from insect muscarinic receptors. Trends Neurosci 1995; 18:104-11
23. Dixon RAF, Sigal IS, Candelore MR, Register RB, Scatergood W, Rands E, Strader CD: Structural features required for ligand binding to the β-adrenergic receptor. EMBO J 1987; 6:3269-75
24. Dixon RAF, Sigal IS, Rands E, Register RB, Candelore MR, Blake AD, Strader CD: Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core. Nature 1987; 326:73-7
25. Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RAF: Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J Biol Chem 1988; 263:10267-71
26. s and increase agonist affinity. J Biol Chem 1987; 262:16439-43
27. 2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 1988; 240:1310-6
28. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ: Structural basis for receptor subtype-specific regulation revealed by a chimeric β3/β2-adrenergic receptor. Proc Natl Acad Sci USA 1993; 90:3665-9
29. Lechleiter J, Hellmiss R, Duerson K, Ennulat D, David N, Clapham D, Peralta E: Distinct sequence elements control the specificity of G protein activation by muscarinic acetylcholine receptor subtypes. EMBO J 1990; 9:4381-90
30. Wess J, Brann MR, Bonner TI: Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover. FEBS Lett 1989; 258:133-6
31. Wess J, Bonner TI, Dörje F, Brann MR: Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Mol Pharmacol 1990; 38:517-23
32. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, Dixon RAF: Allele-specific activation of genetically engineered receptors. J Biol Chem 1991: 266:5-8
33. Curtis CAM, Wheatley M, Bansal S, Birdsall NJM, Eveleigh P, Pedder EK, Poyner D, Hulme EC: Propylbenzilylcholine mustard labels an acidic acid residue in transmembrane helix 3 of the muscarinic receptor. J Biol Chem 1989; 264:489-95
34. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC: Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: Conserved aspartic acids play important roles in receptor function. Mol Pharmacol 1989; 36:840-7
35. Kurtenbach E, Curtis CAM, Pedder EK, Aitken A, Harris ACM, Hulme EC: Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. J Biol Chem 1990; 265:13702-8
36. Wess J, Bonner TI, Brann MR: Chimeric m2/m3 muscarinic receptors: role of carboxyl terminal receptor domains in selectivity of ligand binding and coupling to phosphoinositide hydrolysis. Mol Pharmacol 1990; 38:872-7
37. Wess J, Gdula D, Brann MR: Site-directed mutagenesis of the m3 muscarinic receptor, identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J 1991; 10:3729-34
38. Caulfield MP, Robbins J, Higashida H, Brown DA: Postsynaptic actions of acetylcholine: The coupling of muscarinic receptor subtypes to neuronal ion channels. Prog Brain Res 1993; 98:293-301
39. +-current in a vertebrate neuron. Nature 1980; 283: 673-6
40. αo in rat sympathetic neurones. J Physiol 1994; 477:415-22
41. Brown DA, Marrion NV, Smart TG: On the transduction mechanism for muscarine-induced inhibition of M-current in cultured rat sympathetic neurones. J Physiol 1989; 413:469-88
42. Pennefather P, Lancaster B, Adams PR, Nicoll RA: Two distinct Ca-dependent K currents in bullfrog sympathetic ganglion cells. Proc Natl Acad Sci U S A 1985; 82:3040-4
43. + currents of muscarinic acetylcholine receptor subtypes in NG108-15 cells. Nature 1988; 335:355-7
44. 4 muscarinic receptor mediating Ca-current inhibition in neuroblastoma x glioma hybrid (NG 108-15) cells. BrJ Pharmacol 1991; 104: 39-45
45. + channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins. Pflügers Arch 1986; 407: 264-74
46. + channels. Prog Neurobiol 1992; 39:229-49
47. + channel. J Gen Physiol 1992; 99:961-83
48. Reuveny E, Slesinger PA, Inglese J, Morales JM, Iniguez-Lluhi JA, Lefkowitz RJ, Bourne HR, Jan YN, Jan LY: Activation of the cloned muscarinic potassium channel by G protein βγ subunits. Nature 1994; 370:143-6
49. + channels are activated by βγ subunits and inhibited by the GDP-bound form of α subunit of transducin. Biochem Biophys Res Comm 1994; 200:1484-90
50. Wickman KD, Iniguez-Lluhi JA, Davenport PA, Taussig R, Krapivinsky GB, Linder ME, Gilman AG, Clapham DE: Recombinant G-protein βγ subunits activate the muscarinic-gated atrial potassium channel. Nature 1994; 368:255-7
51. Morishige K, Takahashi N, Jahangir A, Yamada M, Koyama H, Zanclli JS, Kurachi Y: Molecular cloning and functional expression of a novel brain-specific inward rectifier potassium channel. FEBS Lett 1994; 346:251-6
52. Hescheler J, Schultz G: G-proteins involved in the calcium channel signalling system. Curr Opin Neurobiol 1993; 3:360-7
53. Jones SV: Muscarinic receptor subtypes: modulation of ion channels. Life Sci 1993; 52:457-64
54. Brown AM: Membrane-delimited signaling complexes: Direct ion channel regulation by G proteins. J Membr Biol 1993; 131:93-104
55. Inoue M, Yoshii M: Modulation of ion channels by somatostatin and acetylcholine. Prog Neurobiol 1992; 38:203-30
56. Steriade, McCarley RW: Brainstem control of sleep and wakefulness. New York, Plenum Press, 1990
57. Lydic R, Baghdoyan HA: The neurobiology of rapid eye movement sleep, Sleep and Breathing (Lung Biology in Health and Disease, vol 21). Edited by Saunders NA, Sullivan CE. New York, Marcel Dekker, 1994, pp 47-77
58. Eckenstein F, Thoenen H: Production of specific antisera and monoclonal antibodies to choline acetyltransferase: characterization and use for identification of cholinergic neurons. EMBO J 1982; 1: 363-8
59. Ishii K, Oda Y, Ichikawa T, Deguchi T: Complementary DNAs for choline acetyltransferase from spinal cords of rat and mouse: Nucleotide sequences, expression in mammalian cells, and in situ hybridization. Mol Brain Res 1990; 7:151-9
60. Wainer BH, Steininger TL, RobackJD, Burke-Watson MA, Mufson EJ, Kordower J: Ascending cholinergic pathways: Functional organization and implications for disease models. Prog Brain Res 1993; 98:9-30
61. Mesulam M, Geula C, Bothwell MA, Hersh LB: Human reticular formation: Cholinergic neurons of the pedunculopontine and later-odorsal tegmental nuclei and some cytochemical comparisons to forebrain neurons. J Comp Neurol 1989; 281:611-33
62. Semba K, Reiner PB, Fibiger HC: Single cholinergic mesopontine tegmental neurons project to both the pontine reticular formation and the thalamus in the rat. Neuroscience 1990; 38:643-54
63. Losier BJ, Semba K: Dual projections of single cholinergic and aminergic brainstem neurons to the thalamus and basal forebrain in the rat. Brain Res 1993; 604:41-52
64. Foote SL: Extrathalamic modulation of cortical function. Ann Rev Neurosci 1987; 10:67-95
65. de Lacalle S, Lim C, Sobreviela T, Mufson EJ, Hersh LB, Saper CB: Cholinergic innervation in the human hippocampal formation including the entorhinal cortex. J Comp Neurol 1994; 345:321-44
66. Carlsen J, Záborszky L, Heimer L: Cholinergic projections from the basal forebrain to the basolateralamygdaloid complex: A combined retrograde fluorescent and immunohistochemical study J Comp Neurol 1985; 234:155-67
67. Semba K, Reiner PB, McGeer EG, Fibiger HC: Brainstem projecting neurons in the rat basal forebrain: Neurochemical, topographical, and physiological distinctions from cortically projecting neurons. Brain Res Bull 1989; 22:501-9
68. Jourdain A, Seraba K, Fibiger HC: Basal forebrain and mesopontine tegmental projections to the reticular thalamic nucleus: an axonal collateration and immunohistochemical study in the rat. Brain Res 1989; 505:55-65
69. Wonnacott S: The paradox of nicotinic acctylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990; 11:216-9
70. Warburton DM: Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:181-91
71. Ochoa ELM, Li L, McNamee MG: Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine. Mol Neurobiol 1992; 4:251-87
72. Stolerman IP: Behavioural pharmacology of nicotine: Multiple mechanisms. Br J Addict 1991; 86:533-6
73. Corrigall WA: Understanding brain mechanisms in nicotine reinforcement. Br J Addict 1991; 86:507-10
74. Rosecrans JA, Karan LD: Neurobehavioral mechanisms of nicotine action: Role in the initiation and maintenance of tobacco dependence. J Subst Abuse Treat 1993; 10:161-70
75. Swanson LW, Simmons DM, Whiting PJ, Lindstrom J: Immunohistochemical localization of neuronal nicotinic receptors in the rodent central nervous system. J Neurosci 1987; 7:3334-42
76. 3H]nicotine binding sites in rat brain regions: an autoradiographic study. Dev Brain Res 1992; 68:163-74
77. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SVP: Muscarinic acetylcholine receptor subtypes: Localization and structure/function. Prog Brain Res 1993; 98:121-7
78. Levey AI: Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993; 52:441-8
79. Wang SZ, Zhu SZ, Mash DC, El-Fakahany EE: Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Mol Brain Res 1992; 16:64-70
80. Semba K, Reiner PB, McGeer EG, Fibiger HC: Non-cholinergic basal forebrain neurons project to the contralateral basal forebrain in the rat. Neurosci Lett 1988; 84:23-8
81. Záborszky L, Cullinan WE: Hypothalamic axons terminate on forebrain cholinergic neurons: An ultrastructural double-labeling study using PHA-L tracing and ChAT immunocytochemistry. Brain Res 1989; 479:177-84
82. Záborszky L, Heimer L, Eckcnstein F, Leranth C: GABAergic input to cholinergic forebrain neurons: an ultrastructural study using retrograde tracing of HRP and double immunolabeling. J Comp Neurol 1986; 250:282-95
83. Butcher LL, OhJD, Woolf NJ: Cholinergic neurons identified by in situ hybridization histochemistry. Prog Brain Res 1993; 98:1-8
84. Záborszky L, Cullinan WE, Luine VN: Catecholamine-cholinergic interaction in the basal forebrain. Prog Brain Res 1993; 98: 31-49
85. Berridge CW, Arnsten AFT, Foote SL: Noradrenergic modulation of cognitive function: Clinical implications of anatomical, electrophysiological and behavioural studies in animal models. Psych Med 1993; 23:557-64
86. Aston-Jones G, Chiang C, Alexinsky T: Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991; 88:501-20
87. 2 agonist in the rat. J Pharmacol Exp Ther 1992; 263:1046-9
88. 2-adrenoceptor agonists? ANESTHESIOLOGY 1992; 76:873-5
89. 2 agonist, is mediated in the locus coeruleus in rats. ANESTHESIOLOGY 1992; 76:948-52
90. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R, Akaoka H, Drolet G, Astier B, Charléty P, Valentino RJ, Williams JT: Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47-751
91. Foote SL, Berridge CW, Adams LM, Pineda JA: Electrophysiological evidence for the involvement of the locus coeruleus in alerting, orienting and attending. Prog Brain Res 1991; 88:521-32
92. Semba K, Fibiger HC: Afferent connections of the laterodorsal and the pedunculopontine tegmental nuclei in the rat: A retro- and antero-grade transport and immunohistochemical study. J Comp Neurol 1992; 323:387-410
93. Semba K: Aminergic and cholinergic afferents to REM sleep induction regions of the pontine reticular formation in the rat. J Comp Neurol 1993; 330:543-56
94. Jacobs BL, Fornal CA: Activity of brain serotonerigic neurons in the behaving animal. Pharmacol Rev 1991; 43:563-78
95. Honda T, Semba K: Serotonergic synaptic input to cholinergic neurons in the rat mesopontine tegmentum. Brain Res 1994; 647: 299-306
96. Luebke JI, Greene RW, Semba K, Kamondi A, McCarley RW, Reiner PB: Serotonin hyperpolarizes cholinergic low-threshold burst neurons in the rat laterodorsal tegmental nucleus in vitro. Proc Natl Acad Sci USA 1992; 89:743-7
97. Jacobs BL, Fornal CA: 5-HT and motor control: A hypothesis. Trends Neurosci 1993; 16:346-52
98. de Lacalle S, Hersh LB, Saper CB: Cholinergic innervation of the human cerebellum. J Compar Neurol 1993; 328:364-76
99. Baghdoyan HA, Spotts JL, Snyder SG: Simultaneous pontine and basal forebrain microinjections of carbachol suppress REM sleep. J Neurosci 1993; 13:229-42
100. Matsuzaki M, Okada Y, Shuto S-. Cholinergic agents related to para-sleep in acute brain stem preparations. Brain Res 1968; 9: 253-67
101. Sagales T, Erill S, Somino EF: Differential effects of scopolamine and chlorpromazine on REM and NREM sleep in normal male subjects. Clin Pharmacol Ther 1969; 10:522-9
102. Jones BE: The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res 1993; 90:61-71
103. El Mansari M, Sakai K, Jouvet M: Unitary characteristics of presumptive cholinergic tegmental neurons during the sleep-waking cycle in freely moving cat. Exp Brain Res 1989; 76:519-29
104. Kodama T, Takahashi Y, Honda Y: Enhancement of acetylcholine release during paradoxical sleep in the dorsal tegmental field of the cat brain stem Neurosci Lett 1990; 114:277-82
105. Lydic R, Baghdoyan HA: Pedunculopontine stimulation alters respiration and increases ACh release in the pontine reticular formation Am J Physiol 1993; 264:R544-54
106. Jasper HH, Tessier J: Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep. Science 1971; 172:601-2
107. Semba K: The cholinergic basal forebrain: A critical role in cortical arousal, The Basal Forebrain. Edited by Napier TC. New York, Plenum Press, 1991, pp 197-218
108. Williams JA, Comisarow J, Day J, Fibiger HC, Reiner PB: Statedependent release of acetylcholine in rat thalamus measured by in vivo microdialysis. J Neurosci 1994; 14:5236-42
109. Sitaram N, Wyatt RJ, Dawson S, Gillin JC: REM sleep induction by physostigmine infusion during sleep. Science 1976; 191:1281-3
110. Karczmar AG, Longo VG, De Carolis AS: A pharmacological model of paradoxical sleep: the role of cholinergic and monoamine systems. Physiol Behav 1970; 5:175-82
111. Hobson JA, McCarley RW, Wyzinski PW: Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975; 189:55-8
112. Hobson JA, Datta S, Calva JM, Quattrochi J: Acetylcholine as a brain state modulator: Triggering and long-term regulation of REM sleep. Prog Brain Res 1993; 98:389-404
113. Baghdoyan HA, Mallios VJ, Duckrow RB, Mash DC: Localization of muscarinic receptor subtypes in brain stem areas regulating sleep. Neuroreport 1994; 5:1631-4
114. Velasquez-Moctezuma J, Shalauta MD, Gillin JC, Shiromani PJ: Microinjections of nicotine in the medial pontine reticular formation elicits REM sleep. Neurosci Lett 115:265-268, 1990
115. Gillin JC, Salin-Pascual R, Velasquez-Moctezuma J, Shiromani P, Zoltoski R: Cholinergic receptor subtypes and REM sleep in animals and normal controls. Prog Brain Res 98:379-387, 1993
116. Iwamoto ET: Antinociception after nicotine administration into the mesopontine tegmentum of rats: evidence for muscarinic actions. J Pharmacol Exp Ther 251:412-421, 1989
117. Hentall ID, Abate KL, Wojcik RS, Andresen MJ: Nicotinic activity in the interpeduncular nucleus of the midbrain prolongs recovery from halothane anesthesia. Neuropharmacology 31:1299-1304, 1992
118. Karczmar A: Exploitable aspects of cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions, Cholinergic Mechanism and Psychopharmacology. Edited by Jenden D, Hanin I. New York, Plenum Press, 1978, pp 679-708
119. Fibiger HC, Damsma G, Day JC: Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Adv Exp Med Biol 295:399-414, 1991
120. Rasmusson DD: Cholinergic modulation of sensory information. Prog Brain Res 1993; 98:357-64
121. Emre M, Heckers S, Mash DC, Geula C, Mesulam M: Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's disease. J Comp Neurol 1993; 336:117-34
122. Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-17
123. Lucidi-Phillipi CA, Gage FH: The neurotrophic hypothesis and the cholinergic basal forebrain projection. Prog Brain Res 1993; 98:241-9
124. Price DL, Koliatsos VE, Clatterbuck RC: Cholinergic systems: Human diseases, animal models, and prospects for therapy. Prog Brain Res 1993; 98:51-60
125. Pedigo NW, Dewey WL, Harris LS: Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice J Pharmacol Exp Ther 1975; 193: 845-52
126. Yaksh TL, Harty GJ: Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol 1985; 117:81-8
127. Gillberg P, Aquinolius S: Cholinergic, opioid and glycine receptor binding sites localized in human spinal cord by in vitro autoradiography: Changes in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72:299-306
128. Scatton B, Dubois A, Javoy-Agid F, Camus A: Autoradiographic localization of muscarinic cholinergic receptors at various segmental levels of the human spinal cord. Neurosci Lett 1984; 49:239-45
129. Gillberg P, Gordh T, Hartvig P, Jansson I, Pettersson J, Post C: Characterization of the antinociception induced by intrathecally administered carbachol. Pharmacol Toxicol 1989; 64:340-3
130. Franks NP, Lieb WR. Selective actions of volatile general anaesthetics at molecular and cellular levels. BrJ Anaesth 1993; 71: 65-76
131. Franks NP, Lieb WR: Molecular and cellular mechanisms of general anaesthesia. Nature 194; 367:607-14
132. Krnjevic K, Phillis JW: Acetylcholine-sensitive cells in the cerebral cortex. J Physiol (Lond) 1963; 166:296-327
133. Catchlove RFH, Krnjevic K, Maretic H: Similarity between effects of general anesthetics and dinitrophenol on cortical neurons. Can J Physiol Pharmacol 1972; 50:1111-4
134. Smaje JC: General anesthetics and the acetylcholine sensitivity of cortical neurones. Br J Pharmacol 1976; 58:359-66
135. Anthony BL, Dennison RL, Narayanan TK, Aronstam RS: Diethyl ether effects on muscarinic acetylcholine receptor complexes in rat brainstem. Biochem Pharmacol 1988; 37:4041-6
136. Dennison RL, Anthony BL, Narayanan TK, Aronstam RS: Effects of halothane on high affinity agonist binding and guanine nucleotide sensitivity of muscarinic acetylcholine receptors from brainstem of rat. Neuropharmacology 1987; 26:1201-5
137. Anthony BL, Dennison RL, Aronstam RS: Disruption of muscarinic receptor-G protein coupling is a general property of liquid volatile anesthetics. Neurosci Lett 1989; 99:191-6
138. Aronstam RS, Dennison RL: Anesthetic effects on muscarinic signal transduction. Int Anesthesiol Clin 1989; 27:265-72
139. Lin LH, Leonard S, Harris A: Enflurane inhibits the function of mouse and human brain phosphatidylinositol-linked acetylcholine and serotonin receptors expressed in Xenopus oocytes. Mol Pharmacol 1993; 43:941-8
140. 1 G protein-linked receptors in Xenopus oocytes expressing brain mRNA: Role of protein kinase C. Mol Pharmacol 1994; 45:1004-12
141. Durieux ME: Halothane inhibits signaling through m1 muscarinic receptors expressed in Xenopus oocytes. ANESTHESIOLOGY 1995; 82:174-82
142. Durieux ME, Chan CK, Jeter MS: Differential effects of halothane and isoflurane on m1 muscarinic receptors expressed in Xenopus oocytes (abstract). Anesth Analg 1995; S109
143. Anthony BL, Dennison RL, Aronstam RS: Influence of volatile anesthetics on muscarinic regulation of adenylate cyclase activity. Biochem Pharmacol 1990; 40:376-9
144. 2-and opiate effector mechanisms in the locus coeruleus: Intracellular studies in brain slices. Neuropharmacology 1987; 26:793-9
145. Zucker J: Central cholinergic depression reduces MAC for isoflurane in rats. Anesth Analg 1991; 72:790-5
146. Keifer JC, Baghdoyan HA, Becker L, Lydic R: Halothanc decreases pontine acetylcholine release and increases EEG spindles. Neuroreport 1994; 5:577-80
147. Taguchi K, Andresen MJ, Hentall ID: Acetylcholine release from the midbrain interpeduncular nucleus during anesthesia. Neuroreport 1991; 2:789-92
148. Durieux ME: Inhibition by ketaminc of muscarinic acetylcholine receptor function. Anesth Analg 1995; 81:57-62
149. Alphin RS. MartensJR, Dennis DM: Frequency-dependent effects of propofol on atrioventricular nodal conduction in guinea pig isolated heart. ANESTHESIOLOGY 1995; 83:382-94
150. Tigerstedt I, Salmela L, Aromaa U: Double-blind comparison of transdermal scopolamine, droperidol and placebo against postoperative nausea and vomiting. Acta Anaesthesiol Scand 1988; 32: 454-7
151. Baker R, Street LJ, Reeve AJ, Saunders J: Synthesis of azabicyclic pyrazine derivatives as muscarinic agonists and the preparation of a chloropyrazine analogue with functional selectivity at sub-types of the muscarinic receptor. J Chem Soc Chem Commun 1991; 760-2
152. Freedman SB, Patel S, Harley EA, Iversen LL, Baker R, Showell GA, Saunders J, McKnight A, Newberry N, Scholey K, Hargreaves R: L-687,306: A functionally selective and potent M1 receptor agonist. Eur J Pharmacol 1992; 215:135-6
153. Ladinsky H: Acetylcholine receptors: Drugs and molecular genetics. Prog Brain Res 1993; 98:103-11
154. Crowell EB, Ketchum JS: The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther 1967; 8: 409-14
155. Heiser JF, Wilbert DE: Reversal of delirium induced by tricyclic antidepressant drugs with physostigmine. Am J Psychol 1974; 131:1275-7
156. Bidwai AV, Stanley TH, Rogers C, Riet EK: Reversal of diazepam-induced postanesthetic somnolence with physostigmine. ANESTHESIOLOGY 1979; 51:256-9
157. Bidwai AV, Cornelius LR, Stanley TH: Reversal of Innovarinduced somnolence and disorientation with physostigmine. ANESTHESIOLOGY 1976; 44:249-52
158. Massoulié J, Sussman J, Bon S, Silman I: Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 1993; 98:139-46
159. Smith MD, Yang X, Nha J, Buccafusco JJ: Antinociceptive effect of spinal cholinergic stimulation: Interaction with substance P. Life Sci 1989; 45:1255-61
160. 2 receptor systems. ANESTHESIOLOGY 1994; 80:1338-48
161. Zhuo M, Gebhart GF. Tonic cholinergic inhibition of spinal mechanical transmission. Pain 1991; 46:211-22
162. Solomon RE, Gebhart GF: Synergistic antinociceptive interactions among drugs administered to the spinal cord. Anesth Analg 1994; 78:1164-72
163. Abram SE, Winne RP: Intrathecal acetyl cholinesterase inhibitors produce analgesia that is synergistic with morphine and clonidine in rats. Anesth Analg 1995; 81:501-7
164. Williams JS, Tong C, Eisenach JC: Neostigmine counteracts spinal clonidine-induced hypotension in sheep. ANESTHESIOLOGY 1993; 78:301-7
165. Hood DD, Eisenach JC, Tuttle R: Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. ANESTHESIOLOGY 1995; 82:331-43
166. Collins JG: Spinally administered neostigmine - something to celebrate. ANESTHESIOLOGY 1995; 82:327-8
167. Ono S, Kitamura K, Maekawa M, Hirata K, Ano M, Ukai W, Yamafuji T, Narita H: Protective effect of R(-)-1-(benzo[b]thiophen-5-yl)-2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride (T-588), a novel cerebral activator, against experimental cerebral anoxia. Jpn J Pharmacol 1993; 62:81-6
168. Tanaka K, Ogawa N, Asanuma M, Hirata H, Kondo Y, Nakayama N, Mori A: Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch Int Pharmacodyn Ther 1993; 323: 85-96
169. Tanaka K, Ogawa N, Mizukawa K, Asanuma M, Kondo Y, Nishibayashi S, Mori A: Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochem Res 1994; 19:117-22
170. Schultz JA, Hoffman WE, Albrecht RF: Sympathetic stimulation with physostigmine worsens outcome from incomplete brain ischemia in rats. ANESTHESIOLOGY 1993; 79:114-21
171. Vilaró MT, Mengod G, Palacios JM: Advances and limitations of the molecular neuroanatomy of cholinergic receptors: The example of multiple muscarinic receptors. Prog Brain Res 1993; 98:95-101